Mineralys Therapeutics, Inc. Common Stock
$ 26.99
0.52%
06 Aug - close price
- Market Cap 2,379,397,000 USD
- Current Price $ 26.99
- High / Low $ 27.63 / 26.46
- Stock P/E N/A
- Book Value 7.74
- EPS -1.97
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.31 %
- 52 Week High 47.65
- 52 Week Low 12.59
About
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.
Analyst Target Price
$49.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-12 | 2025-11-10 | 2025-08-12 | 2025-05-12 | 2025-02-12 | 2024-11-11 | 2024-08-13 | 2024-05-09 | 2024-03-21 | 2023-11-07 | 2023-08-07 |
| Reported EPS | -0.47 | -0.4 | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.7 | -0.61 | -0.57 | -0.31 |
| Estimated EPS | -0.44 | -0.94 | -0.61 | -0.74 | -0.98 | -1.08 | -0.83 | -0.7 | -0.67 | -0.82 | -0.76 | -0.72 |
| Surprise | -0.03 | 0.54 | 0.09 | 0.08 | 0.19 | 0.1 | -0.3 | -0.13 | -0.03 | 0.21 | 0.19 | 0.41 |
| Surprise Percentage | -6.8182% | 57.4468% | 14.7541% | 10.8108% | 19.3878% | 9.2593% | -36.1446% | -18.5714% | -4.4776% | 25.6098% | 25% | 56.9444% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.57 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MLYS
2026-08-07 00:41:35
FMR LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 5.1% in Mineralys Therapeutics, Inc. (MLYS), which accounts for 4,461,689.46 shares of common stock. The filing specifies that FMR LLC holds sole voting power over 4,461,164.00 shares and sole dispositive power over all 4,461,689.46 shares. Abigail P. Johnson also reports sole dispositive power over the same number of shares, but no voting power.
2026-08-05 10:42:23
Mineralys Therapeutics (MLYS) is set to report its Q2 2026 earnings on August 11, 2026, with its stock currently seen as 47.9% undervalued by analysts, suggesting a fair value of $50.88 compared to its recent close of $26.50. This valuation hinges on the potential of its lead drug, lorundrostat, for uncontrolled and resistant hypertension, which could transition the company from R&D to revenue generation. However, the company faces risks related to approval timing and competition, despite long-term shareholder returns of nearly 100%.
2026-08-04 12:11:21
Mineralys Therapeutics (Nasdaq: MLYS) announced it will report its second-quarter 2026 financial results after market close on Tuesday, August 11, 2026. The company will host a conference call and live webcast for investors and analysts at 4:30 p.m. ET on the same day to discuss the results. This announcement provides details for accessing the call and webcast, as well as an overview of the company's focus on developing medicines for hypertension and related conditions.
2026-08-04 12:10:37
Mineralys Therapeutics will announce its financial results for the second quarter ended June 30, 2026, after the financial markets close on Tuesday, August 11, 2026. The biopharmaceutical company will also host a conference call on the same day at 4:30 p.m. ET to discuss the results. Interested parties can access the call via phone or live webcast.
2026-08-04 08:00:00
Mineralys Therapeutics, Inc. announced it will report its financial results for the second quarter ended June 30, 2026, after the financial markets close on Tuesday, August 11, 2026. The company will host a conference call on the same day at 4:30 p.m. ET to discuss the results. Mineralys Therapeutics focuses on developing treatments for hypertension and aldosterone-related conditions.
2026-08-03 18:10:20
Renaissance Technologies LLC increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 18.8% in the first quarter, acquiring an additional 60,700 shares to reach a total of 382,800 shares valued at approximately $10.37 million. Despite significant insider selling totaling over $6.2 million, analyst sentiment remains a "Moderate Buy" with an average price target significantly above the current trading price. Mineralys Therapeutics, a clinical-stage biopharmaceutical company, focuses on treatments for hypertension and chronic kidney diseases.
